我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
11
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
9
81.8%
尚未招募
1
9.1%
招募中
暂无批准数据
- A meta-analysis of 7 studies showed subcutaneous rituximab had similar efficacy to intravenous rituximab in non-Hodgkin lymphoma patients. - The analysis found no significant difference in grade 3 or higher adverse events between subcutaneous and intravenous rituximab. - Subcutaneous rituximab was associated with lower total costs, pharmacy technique costs, and administration costs compared to intravenous rituximab. - Subcutaneous rituximab also demonstrated a lower total process time, suggesting increased efficiency in administration.
